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Retinoids can induce terminal differentiation in a subset of neuronal cancer cells, but what determines
response has been unclear. In a recent issue of Cell, Ho¨lzel and colleagues show that hyperactive RAS
signaling imparts retinoid resistance to neuroblastoma cells, which can be reversed by inhibiting MAPK,
suggesting new therapeutic opportunities.Retinoids are natural or synthetic analogs
of vitamin A that have shown promise as
cancer therapeutics. These molecules
bind to the retinoid acid receptors (RARs)
and retinoid X receptors (RXRs) and
mediate gene transcription in a ligand-
dependant manner through retinoic acid
response elements (Altucci and Grone-
meyer, 2001). As a seminal example of
retinoid-based therapies, acute promye-
locytic leukemia (APL), a disease defined
by chromosomal translocations that lead
to the production of aberrant RARa fusion
proteins resulting in a blockade of normal
myeloid cell differentiation, can be effec-
tively eradicated by treatment with all-
trans retinoic acid (ATRA) combined with
chemotherapy (Fenaux et al., 2001).
Although ATRA is now a mainstay of
APL therapy, the retinoids have mainly
been investigated as potential chemopre-
ventative agents, and there are no other
examples where retinoids have proven
useful in treating established diseases.
In addition, it should be emphasized that
the experience in APL is part of the
emerging theme of combinatorial strate-
gies as a key component of maximally
exploiting molecularly targeted therapies.
Neuroblastoma is an embryonal tumor
of the developing autonomic nervous sys-
tem that exhibits diverse clinical behav-
iors ranging from spontaneous regression
to relentless progression. Survival for
children with high-risk neuroblastoma
(50% of cases) has shown only modest
improvement despite dramatic escala-
tions in the intensity of cytotoxic therapy
over the past two decades, but there
have been recent advances in improving
outcomes with targeted therapies de-
signed to eradicate minimal residual dis-
ease after chemotherapy (Maris, 2010).It has been known for decades that reti-
noids can drive terminal differentiation of
some neuroblastoma cells in vitro, but
strikingly many cell models show com-
plete resistance to the effects of retinoids.
Despite the observation of heterogeneity
in response to retinoids, extensive pre-
clinical evaluation of these compounds
led to a phase 1 trial of isotretinoin
(13-cis retinoic acid) in neuroblastoma
patients after myeloablative consolida-
tion, showing it was well tolerated with
a hint of antitumor activity (Villablanca
et al., 1995). The efficacy of isotretinoin
was then tested in a phase 3 randomized
trial with a factorial design after a random-
ization to myeloablative or continuation
chemotherapy. The cohort of patients as-
signed to receive posttransplant therapy
with isotretinoin had a modest but signifi-
cantly improved 3 year event-free survival
probability of 46% ± 6% versus 29% ±
5% (p = 0.027) (Matthay et al., 1999),
although this was even more marginal on
further follow-up (5 year EFS = 42% ±
5% versus 31% ± 5%; p = NS) (Matthay
et al., 2009). Subsequently, addition of
an immunotherapy regimen targeting the
cell-surface ganglioside GD2 with cyto-
kines further improved outcome (A.L. Yu
et al., 2009, J. Clin. Oncol., abstract),
thus the combination of isotretinoin with
immunotherapy is now considered a
standard approach to eliminating rare
residual tumor cells that may survive
intensive cytotoxic therapy.
In a recent issue of Cell, Ho¨lzel and
colleagues reported the identification of
potential modulators of sensitivity to reti-
noid therapy by using an RNAi-based
loss-of-function genetic screen (Ho¨lzel
et al., 2010). Here, they specifically
address the clinical problem that althoughCancer Cell 18isotretinoin appears to be an active agent,
it fails to prevent relapse in a significant
percentage of neuroblastoma patients.
In a series of well-controlled experiments,
the investigators identified NF1 as the
lead candidate gene for influencing reti-
noic acid-induced differentiation in neuro-
blastoma cell models, with depletion of
NF1 resulting in loss of retinoid-induced
differentiation capacity. This group re-
cently showed that ZNF423, a component
of the RAR/RXR transactivator complex,
is essential for the response to retinoids
in neuroblastoma (Huang et al., 2009).
Ho¨lzel connected these observations
through the MEK-ERK component of the
MAPK signaling network. The authors
showed that hyperactive Ras results in
suppressed expression of ZNF423, and
thus decreased transcription of retinoic
acid response genes (Figure 1). Although
MAPK signaling has been implicated in
modulating retinoid responsiveness pre-
viously, Ho¨lzel and colleagues provide
a very clear link between common cancer
driving mutations such as in ras hyperac-
tivation and/or receptor tyrosine kinase
mutations and insensitivity of cells to reti-
noid therapy.
There are several important clinical
implications related to these findings,
some of which are tested in the Ho¨lzel
et al. paper. The observation that NF1
was the top hit in the siRNA screen led
to the search for mutations in primary
neuroblastoma samples. Although the
authors did find evidence for inactivating
mutations and homozygous deletions,
these were rare, consistent with past
reports (The et al., 1993). Ongoing
full-genome sequencing efforts as part
of the neuroblastoma TARGET pro-
ject (http://target.cancer.gov) will further, August 17, 2010 ª2010 Elsevier Inc. 103
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Figure 1. The Extracellular Signal-Related Kinase Component of the Mitogen-Activated
Protein Kinase Pathway
The extracellular signal-related kinase (ERK) component of the mitogen-activated protein kinase (MAPK)
pathway is depicted in simplified form. Activation of this pathway occurs with hyper-activated ras through
a variety of mechanisms, including loss of the NF1 tumor suppressor that keeps ras locked into the GTP-
bound (active) state, as well as through signaling through receptor tyrosine kinases (RTKs) via guanine
exchange factors (GEFs) such as SOS. Canonical ERK signaling promotes cellular proliferation via tran-
scriptional regulation of multiple transcription factors such as Jun and Fos. Although MAPK signaling
has a multitude of additional effects in a cell context-specific manner, it is now clear that at least in neuro-
blastoma cells, activatedMAPK signaling suppresses the transcription of ZNF423, a key component of the
retinoic acid receptor complex, thus rendering cells insensitive to the effects of the retinoid ligands that
need to bind to the RAR/RXR/ZNF423 coactivator complex to drive transcription at retinoic acid response
elements (RAREs).
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epigenetic inactivation of NF1 in neuro-
blastoma, as well as the frequency of
other alterations that may converge
on MAPK pathway hyperactivation. In
addition, the authors explore NF1 and
ZNF423 as prognostic biomarkers. They
show convincingly that low mRNA
expression of both genes is associated
with a significantly decreased patient
survival probability. Although this may
not be too surprising because low NF1
and ZNF423 reflects hyperactivated Ras/
MAPK, and the clinical utility of stratifying
traditional therapy based on these mRNA
signatures is far from certain, the findings
do suggest that certain neuroblastomas
are hardwired to be resistant to retinoid
therapy from the time of diagnosis and
that NF1 and ZNF423 expression levels
may be a robust predictor of responsive-
ness to isotretinoin therapy. Finally and104 Cancer Cell 18, August 17, 2010 ª2010 Eperhaps most importantly, Ho¨lzel and
colleagues take the first steps in exploring
whether their findings might be leveraged
therapeutically. The authors show that
pharmacologic inhibition of MEK can
sensitize neuroblastoma cells genetically
engineered to be resistant to retinoid-
induced terminal differentiation. Several
MEK inhibitors are in development, and
a dual MEK1/2 inhibitor recently showed
tolerabiltiy and evidence for single agent
antitumor activity in an early phase 1/2
clinical trial (J.R. Infante et al., 2010,
J. Clin. Oncol., abstract).
Although the data presented by Ho¨lzel
and colleagues seem readily translatable,
several important questions and chal-
lenges will need to be addressed before
the work here can impact patient care.
First, prospective validation of NF1 and
ZNF423mRNA levels as the most reliable
and robust biomarker of retinoid respon-lsevier Inc.siveness is required and will need to
be compared to other potential bio-
markers such as phospho-MEK. It will
also be important to determine whether
the markers of retinoid resistance are
dynamic; i.e., is MAPK pathway activation
also a mechanism of acquired resistance
to isotretinoin therapy, or is it solely
a collateral event of oncogenic mutations
that are driving tumorigenesis? Serial
measurement of NF1 and ZNF423 levels
(or other markers) in tumor cells during
the course of treatment and at relapse
will be needed to understand how best
to utilize this combinatorial approach in
the clinic. It will also be critically important
to determine early on how combined
MEK inhibition with isotretinoin will fit
into the overall neuroblastoma treatment
strategy. Although isotretinoin alone was
originally designed as a postcytotoxic
therapy maintenance biotherapy, the
big problem in neuroblastoma currently
is achieving an initial quality remission.
Indeed, there has been little advancement
in improving chemotherapeutic remission
induction, and no molecularly targeted
agents have been incorporated into the
initial phases of high-risk neuroblastoma
therapy. Although integration of a MEK
inhibitor with isotretinoin at the end of
therapy may ultimately make the most
sense, it may be possible to define
a cohort of patients at diagnosis with
tumors primed to respond to this combi-
nation therapy.
In a broader sense, this work clearly
demonstrates the power of unbiased
genetic screens to identify tractable
therapeutic strategies for human cancer.
By focusing on current clinical realities,
such as the fact that isotretinoin is
considered a standard therapy for
neuroblastoma, but one with marginal
clinical benefit, investigators can not
only uncover novel insights into themech-
anisms underlying human cancer, but
also identify rapidly translatable hypoth-
eses because they build on existing para-
digms. This approach to targeted thera-
peutics has the potential to advance the
field more rapidly than developing a drug
target in a vacuum devoid of considering
current clinical practice.REFERENCES
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Two recent studies identified loss-of-function mutations in the histone H3 methyltransferase EZH2 in
myelodysplastic syndromes andmyeloproliferative neoplasms, provided further demonstration of mutations
in epigenetic modifiers in myeloid malignancies, and suggest EZH2 functions as a tumor-suppressor gene in
these malignancies rather than an oncogene as in some other malignancies.Laboratory studies have implicated epi-
genetic dysregulation as a common path-
ogenetic mechanism in myelodysplastic
syndromes (MDS), myeloproliferative
neoplasms (MPNs), and acute myeloid
leukemia (AML). Notably, genome-wide
methylation studies have identified a set
of genes recurrently targeted by aberrant
promoter hypermethylation in AML (Fig-
ueroa et al., 2010). Recent studies have
shown that chromosome translocations
involving MLL and JARID1A found in
myeloid malignancies result in dysregula-
tion of chromatin state and resultant
activation of genes that contribute to
leukemogenesis (Krivtsov et al., 2008;
Wang et al., 2009). In addition, hypome-
thylating agents (5-azacytidine and deci-
tabine) are approved for the treatment
MDS and AML, illustrating the therapeutic
relevance of epigenetic alterations in
myeloid malignancies. However, until re-
cently, somatic mutations that directly
dysregulate the epigenetic state of
leukemic cells but are not chromosomal
rearrangements had not been reported.
Two groups led by Nicholas Cross and
Joop Jansen recently reported identifica-tion of recurrent somatic EZH2 mutations
in MDS, MPNs, and MDS/MPN overlap
disorders (Ernst et al., 2010; Nikoloski
et al., 2010). Alterations in the long arm
of chromosome 7 are common in MDS
and AML and are associated with adverse
outcome of these patients. Both groups
first used high-resolution SNP arrays to
characterize regions of acquired unipa-
rental disomy (aUPD) and microdeletions
involving chromosomal locus 7q36, which
includes the EZH2 gene. They then per-
formed gene resequencing of EZH2 and
identified somatic frameshift, nonsense,
and missense mutations in MDS, MDS/
MPN, and MPN, with and without con-
comitant chromosome 7 alterations. The
identified missense mutations most com-
monly affected the CXC-SET domain,
which is required for histone methyltrans-
ferase activity, or domain II, which is
necessary for binding to SUZ12, of
EZH2. Importantly, they did not identify
EZH2 mutations in AML with chromo-
some 7 abnormalities, including those
with chromosome 7 aUPD. These results
suggest the existence of an additional,
not yet identified, tumor suppressorgene for MDS, MPN, and AML on chro-
mosome 7. This is consistent with pre-
vious cytogenetic studies of chromosome
7 deletions in MDS and AML that have
delineated several regions of common
deletion on chromosome 7, only one of
which includes the EZH2 locus (Le Beau
et al., 1996). In addition, both current
studies suggest that patients having
MDS with EZH2 mutations have wors-
ened overall survival compared to those
having MDS without EZH2 mutations,
independent of the presence or absence
of cytogenetic abnormalities involving
chromosome 7.
The genetic data implicating EZH2 in
the pathogenesis ofmyeloidmalignancies
is in contrast to that observed in other
malignancies. A recent study employed
whole transcriptome resequencing to
identify somatic EZH2 mutations in lym-
phoma and found that all mutations
affected a specific residue within the
EZH2 SET domain, tyrosine 641 (Morin
et al., 2010). However, tyrosine 641 was
not identified as a mutational hotspot in
MDS and MPN by Cross, Jansen, and
colleagues. Moreover, previous studies, August 17, 2010 ª2010 Elsevier Inc. 105
